Emma Reeve Sells 8,642 Shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) Stock

Share on StockTwits

Constellation Pharmaceuticals Inc (NASDAQ:CNST) CFO Emma Reeve sold 8,642 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $35.04, for a total transaction of $302,815.68. Following the completion of the sale, the chief financial officer now directly owns 200 shares of the company’s stock, valued at approximately $7,008. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Emma Reeve also recently made the following trade(s):

  • On Thursday, February 13th, Emma Reeve sold 5,521 shares of Constellation Pharmaceuticals stock. The shares were sold at an average price of $35.06, for a total transaction of $193,566.26.

NASDAQ:CNST opened at $36.06 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 5.19 and a current ratio of 5.19. The stock has a market capitalization of $1.49 billion, a P/E ratio of -11.48 and a beta of 6.93. The company has a 50 day moving average price of $38.67 and a 200 day moving average price of $24.33. Constellation Pharmaceuticals Inc has a fifty-two week low of $6.01 and a fifty-two week high of $59.49.

Several analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Constellation Pharmaceuticals in a research note on Tuesday, December 10th. Robert W. Baird reissued an “outperform” rating and issued a $65.00 price target (up previously from $35.00) on shares of Constellation Pharmaceuticals in a research note on Tuesday, December 10th. SunTrust Banks assumed coverage on shares of Constellation Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $50.00 price target for the company. Finally, Cowen assumed coverage on shares of Constellation Pharmaceuticals in a research note on Friday, February 7th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. Constellation Pharmaceuticals currently has an average rating of “Buy” and an average target price of $44.09.

Several large investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its position in shares of Constellation Pharmaceuticals by 2.4% during the 4th quarter. Rhumbline Advisers now owns 20,331 shares of the company’s stock worth $958,000 after purchasing an additional 471 shares during the period. Bank of Montreal Can boosted its position in shares of Constellation Pharmaceuticals by 43.0% during the 4th quarter. Bank of Montreal Can now owns 1,937 shares of the company’s stock worth $91,000 after purchasing an additional 582 shares during the period. Victory Capital Management Inc. boosted its position in shares of Constellation Pharmaceuticals by 43.4% during the 4th quarter. Victory Capital Management Inc. now owns 2,199 shares of the company’s stock worth $73,000 after purchasing an additional 666 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of Constellation Pharmaceuticals during the 4th quarter worth approximately $36,000. Finally, UBS Group AG boosted its position in shares of Constellation Pharmaceuticals by 15.9% during the 4th quarter. UBS Group AG now owns 13,905 shares of the company’s stock worth $655,000 after purchasing an additional 1,912 shares during the period. 49.91% of the stock is owned by hedge funds and other institutional investors.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Featured Story: Penny Stocks, What You Need To Know

Insider Buying and Selling by Quarter for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.